The merger had hit a roadblock with minority shareholders of Parke-Davis objecting to the swap ratio. They alleged that the scheme of merger was not approved with the requisite majority as per the Companies Act, 1956.
Kewal Handa, executive director (finance) of Pfizer, said:
